生命科学资讯
生物技术与制药领域的最新动态
FDA rejects Disc Medicine's rare disease drug despite granting it a commissioner voucher
六家生物科技公司递交港交所上市申请；法拉第制药公司关闭运营
Six biotechs file for HKEX listing; Faraday Pharmaceuticals shutters
康帕斯通路公司因第二阶段抑郁症治疗突破股价飙升
Compass Pathways soars on second Phase 3 depression hit
Ocular Therapeutix公司Axpaxli疗效优于Eylea，股价应声下跌。
Ocular Therapeutix’ Axpaxli shows superiority over Eylea, shares sink
勃林格殷格翰停止吸入式囊性纤维化基因疗法研发。
Boehringer Ingelheim stops work on inhaled cystic fibrosis gene therapy
Moderna与FDA之争；赛诺菲CEO保罗·哈德森离职；临床试验为何如此昂贵；及其他动态
Moderna vs FDA; Paul Hudson out at Sanofi; Why clinical trials are so costly; and more
吉利德以8000万美元预付款从中国基石药业引进抗癌药物。
Gilead gets cancer drug from China-based Genhouse for $80M upfront
五角大楼将药明康德列入中国军方关联企业名单后又移除。
Pentagon adds, then withdraws, WuXi AppTec to Chinese military list
礼来就retatrutide分类裁决提起上诉，此案或影响复方制剂行业。
Lilly appeals retatrutide classification ruling in case that could impact compounders
表观遗传编辑初创公司Moonwalk转向siRNA技术应对肥胖问题
Epigenetic editing startup Moonwalk shifts focus to siRNA for obesity
灵北偏头痛预防药物二期试验成功，推动新疗法类别进展。
Lundbeck migraine prevention drug succeeds in Phase 2, advancing new therapy class
Moderna流感疫苗困境令2028年盈亏平衡指引蒙上阴影。
Moderna's flu shot dilemma muddies 2028 break-even guidance
礼来公司在美国批准前囤积价值15亿美元的减肥药丸。
Lilly stockpiles $1.5B worth of weight loss pill ahead of US approval
Immunic公司完成私募融资；Vertex囊性纤维化药物在幼童中展现积极数据
Immunic's private placement; Vertex's cystic fibrosis data in young kids
保罗·哈德森未能带领赛诺菲跨越障碍；PROTAC开发商Arvinas任命新CEO
Paul Hudson couldn’t quite get Sanofi over the hump; PROTAC developer Arvinas appoints CEO
PTC Therapeutics撤回美国对杜氏肌营养不良症治疗药物Translarna的申请。
PTC Therapeutics withdraws US filing for troubled Duchenne treatment Translarna
Ultragenyx在经历艰难的2025年后将裁员约130人
Ultragenyx to lay off about 130 employees after rough 2025
Icon公司披露内部会计调查后股价暴跌40%
Icon's stock drops 40% after disclosing internal accounting probe
艾伯维就肉毒杆菌素入选IRA谈判提起法律诉讼。
AbbVie sues over selection of Botox for IRA negotiations